ENTRY       D11601                      Drug
NAME        Tafasitamab (USAN/INN);
            Tafasitamab (genetical recombination) (JAN);
            Tafasitamab-cxix;
            Monjuvi (TN);
            Minjuvi (TN)
PRODUCT     MONJUVI (MorphoSys US)
FORMULA     C6550H10092N1724O2048S52
EXACT_MASS  147332.4026
MOL_WEIGHT  147423.9175
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVKPGGSLKL SCAASGYTFT SYVMHWVRQA PGKGLEWIGY INPYNDGTKY
            NEKFQGRVTI SSDKSISTAY MELSSLRSED TAMYYCARGT YYYGTRVFDY WGQGTLVTVS
            SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
            GPDVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF
            NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK ALPAPEEKTI SKTKGQPREP QVYTLPPSRE
            EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR
            WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
            (Light chain)
            DIVMTQSPAT LSLSPGERAT LSCRSSKSLQ NVNGNTYLYW FQQKPGQSPQ LLIYRMSNLN
            SGVPDRFSGS GSGTEFTLTI SSLEPEDFAV YYCMQHLEYP ITFGAGTKLE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H96, H148-H204, H224-L219, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'219, H'265-H'325, H'371-H'429, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  TYPE      Peptide
REMARK      ATC code: L01FX12
            Product: D11601<US>
EFFICACY    Antineoplastic, Anti-CD19 antibody
  DISEASE   Diffuse large B-cell lymphoma (CD19-directed) [DS:H02434]
  TYPE      Monoclonal antibody
COMMENT     Treatment of CD19-positive hematologic malignancies
TARGET      CD19 [HSA:930] [KO:K06465]
  PATHWAY   hsa04151(930)  PI3K-Akt signaling pathway
            hsa04640(930)  Hematopoietic cell lineage
            hsa04662(930)  B cell receptor signaling pathway
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX12 Tafasitamab
                  D11601  Tafasitamab (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Tafasitamab
                D11601  Tafasitamab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD19
                 D11601  Tafasitamab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11601
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11601
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11601
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D11601
DBLINKS     CAS: 1422527-84-1
            PubChem: 405226468
///
